Fmr LLC Dyne Therapeutics, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Fmr LLC holds 5,318,963 shares of DYN stock, worth $153 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

5,318,963

Previous 3,218,393 65.27%

Holding current value

$153 Million

Previous $91.4 Million 105.44%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$23.65 - $35.63 $49.7 Million - $74.8 Million	2,100,570 Added 65.27%	5,318,963 $188 Million
Q1 2024 May 13, 2024	BUY	$13.06 - $29.18 $25.3 Million - $56.5 Million	1,935,581 Added 150.89%	3,218,393 $91.4 Million
Q4 2023 Feb 13, 2024	BUY	$6.62 - $13.64 $2.89 Million - $5.95 Million	436,452 Added 51.57%	1,282,812 $17.1 Million
Q3 2023 Nov 13, 2023	SELL	$8.6 - $12.18 $455,215 - $644,711	-52,932 Reduced 5.89%	846,360 $7.58 Million
Q2 2023 Aug 11, 2023	BUY	$8.53 - $14.28 $4.18 Million - $7 Million	490,236 Added 119.85%	899,292 $10.1 Million
Q1 2023 May 11, 2023	SELL	$10.88 - $15.0 $1.8 Million - $2.48 Million	-165,064 Reduced 28.75%	409,056 $4.71 Million
Q4 2022 Feb 13, 2023	BUY	$9.37 - $13.8 $4.69 Million - $6.91 Million	500,878 Added 683.87%	574,120 $6.65 Million
Q3 2022 Nov 10, 2022	BUY	$7.2 - $15.17 $2,944 - $6,204	409 Added 0.56%	73,242 $930,000
Q2 2022 Aug 12, 2022	BUY	$4.36 - $10.5 $287 - $693	66 Added 0.09%	72,833 $500,000
Q1 2022 May 13, 2022	BUY	$6.52 - $12.27 $362,296 - $681,807	55,567 Added 323.06%	72,767 $701,000
Q4 2021 Feb 14, 2022	BUY	$11.89 - $16.07 $204,508 - $276,404	17,200 New	17,200 $205,000

Others Institutions Holding DYN

# of Institutions

204

Shares Held

105M

Call Options Held

82.7K

Put Options Held

24.8K

View Full List

About Dyne Therapeutics, Inc.

Ticker DYN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,765,400
Market Cap $1.49B
Description
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...

More about DYN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account